FDA approves Tavalisse to treat chronic immune thrombocytopenia . Rigel Pharma.
Rigel Pharmaceuticals, Inc. announced that the FDA approved Tavalisse (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Tavalisse is an oral spleen tyrosine kinase (SYK) inhibitor that targets the underlying autoimmune cause of the disease by impeding platelet platelet destruction, providing an important new treatment option for adult patients with chronic ITP.
Rigel plans to launch Tavalisse in the United States in late May 2018.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins